Sandra A Jablonski

US Patent:

6593098, Jul 15, 2003

Filed:

Jun 1, 2000

Appl. No.:

09/555554

Inventors:

Timothy Yen - Havertown PA
Gordon Chan - Cheltenham PA
Sandra Jablonski - Philadelphia PA

Assignee:

Fox Chase Cancer Center - Philadelphia PA

International Classification:

C12Q 148

US Classification:

435 15, 435194, 435 6, 4352523, 4353201, 435325, 536 231, 536 232

Abstract:

Novel human BUB genes and their encoded proteins are provided herein. The kinases encoded by the disclosed BUB1A and BUB1B genes play a pivotal role in mitotic checkpoint control. BUB3 is a substrate of these kinases, BUB genes and their encoded proteins provide valuable therapeutic targets for the design of anti-proliferative agents which inhibit the aberrant cellular proliferation observed in tumor cells.

US Patent:

20220257609, Aug 18, 2022

Filed:

Feb 23, 2022

Appl. No.:

17/678754

Inventors:

- Washington DC, US
Louis WEINER - Washington DC, US
Sandra JABLONSKI - Silver Spring MD, US
Sandeep NADELLA - Alexandria VA, US
Shangzi WANG - Derwood MD, US

Assignee:

GEORGETOWN UNIVERSITY - Washington DC

International Classification:

A61K 31/5513
A61P 35/00
A61K 31/198
C07K 16/28

Abstract:

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

US Patent:

20200383996, Dec 10, 2020

Filed:

Mar 15, 2018

Appl. No.:

16/493882

Inventors:

- Washington DC, US
Louis Weiner - Washington DC, US
Sandra Jablonski - Silver Spring MD, US
Sandeep Nadella - Alexandria VA, US
Shangzi Wang - Derwood MD, US

Assignee:

GEORGETOWN UNIVERSITY - Washington DC

International Classification:

A61K 31/5513
A61K 31/198
C07K 16/28
A61P 35/00

Abstract:

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. Also provided are methods for increasing sensitivity of a (CCK) receptor-expressing cancerous tumor in a subject to immunotherapy.